Once-a-day therapy for HIV infection: A controlled, randomized study in antiretroviral-naive HIV-1-infected patients

Antiviral Therapy

Volumn 8, Issue 4, 2003, Pages 339-346

  Moggiolo, Franco ^a   Ripamonti, Diego ^a   Gregis, Gianpietro ^a   Quinzan, Gianpaolo ^a   Callegaro, Annapaola ^a   Arici, Claudio ^a   Ravasio, Laura ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LEUKOCYTE COUNT; LIPODYSTROPHY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH DISEASE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0042324086     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Keiser P & Nassar N. Drug evaluation: trizivir. Expert Opinion on Pharmacotherapy 2002; 3:619-624.
2. Squires K, Gatell J, Piliero P, Sanne I, Wood R & Schnittman SM. 48-week safety and efficacy results from a Phase II study on once-daily HIV-1 protease inhibitor (PI) BMS-232632. 8th Conference on Retroviruses & Opportunistic Infections (CROI), Chicago, Ill., USA, February 2001; Abstract 15.
3. Schooley R, Ruane P, Myers R, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E & Cheng AK for the study 902 Team. Tenofovir DF in antiretroviral experienced patients: results from a 48 week randomized, double blind study. AIDS 2002; 14:1257-1264.
4. Maggiolo F, Rizzi M, Finazzi G & Suter F. Once-a-day indinavir therapy in virologically controlled HIV positive persons. 13th International AIDS Conference, Durban, South Africa, July 2000; Abstract TuPpA1155.
5. Cardiello P, Van Heeswijk R, Monhaphol T, Ubolyam S, Cooper D, Lange J & Phanuphak P. HIV-NAT 001.3: the safety, efficacy and pharmacokinetics (PK) of 1,600 mg saquinavir (soft-gelatin capsules; SQV-SGC) plus low dose ritonavir (RTV, 100 mg) in a once-daily (QD) dosing regimen in HIV-1. 1st IAS Conference on HIV Pathogenesis & Treatment, Buenos Aires, Argentina, July 2001; Abstract 59.
6. Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Pravettoni G, Rizzi L & Suter F for the Once Study Group. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antiviral Therapy 2001; 6:249-253.
7. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, Morlat P, Journot V, Decazes JM & Chene G for the Montana Study Group. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 2000; 182:599-602.
8. Landman R, Schiemann R, Thiam S, Delaporte E, Mboup S, Vray M, Badiane S, Coulaud JP, Peytavin G, Girard PM & Ndoye I for the ANRS 12-04 Study Group. Evaluation at 6 months of a once-a-day HAART regimen in treatment-naive HIV-1-infected adults in Senegal (ANRS 12-04 study). 8th Conference on Retroviruses & Opportunistic Infections (CROI), Chicago, Ill., USA, February 2001; Abstract 491.
9. Jordan W, Jefferson R, Yemofio F, Tolbert L, Conlan V, Carroll H, Green DC & Green A. Nevirapine (NVP) + efavirenz (EFV) + didanosine (ddI): a very simple, safe, and effective once-daily regimen. 13th International AIDS Conference, Durban, South Africa, July 2000; Abstract TuPeB3207.
10. Hsieh SM, Hung CC, Lu PL, Chen MY & Chang SC. Preliminary experience of adverse drug reactions, tolerability, and efficacy of a once-daily regimen of antiretroviral combination therapy. Journal of Acquired Immune Deficiency Syndromes 2000; 24:287-288.
11. Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin DS, Dusak BA, Tolson JM, Stevens M, Yuen GJ & Rooney JF, for the Intercompany Collaboration for AIDS Drug Development 604 Team. Once-daily quadruple-drug therapy with adefovir dipivoxil, lamivudine, didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. Journal of Infectious Diseases 2002; 186:1028-1033.
12. Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M & Moroni M, ICONA Study Group. When to start highly active antiretroviral therapy in chronically infected patients: evidence from the ICONA study. AIDS 2001, 15:883-890.
13. Carr A & Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
14. Moyle GJ & Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Safety 1999; 20:299-321.
15. Lerner BH, Gulick RM & Dubler NN. Rethinking non-adherence: historical perspectives on triple-drug therapy for HIV disease. Annals of Internal Medicine 1998; 129:573-578.
16. Claxton AJ, Cramer J & Pierce C. A systematic review of the association between dose regimens and medication compliance. Clinical Therapy 2001; 23:1296-1310.
17. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. Journal of International Medical Research 1994; 22:266-272.
18. Bartlett JA, DeMasi R, Quinn J, Moxham C & Rosseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-1377.
19. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clinical Infectious Diseases 2001; 33:865-872.
20. Sanne I, Piliero P, Wood R, Kelleher T, Cross A, Mongillo A & Schnittman S. Safety and antiviral efficacy of a novel once-daily HIV-1 protease inhibitor BMS-232632: 24-week results of a Phase II clinical trial. 40th Interscience Conference on Antimicrobial Agents & Chemotherapy, Toronto, Canada, September 2000; Abstract 691.
21. Schooley R, Ruane P, Myers R, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E & Cheng AK. Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral experienced patients: a 48-week analysis of a randomized, double blind, placebo controlled study. AIDS 2000; 14(Suppl. 4):S6-S7.
22. Sension M, Bellos N, Johnson J, Sepulveda G, Santana J, Ames M & Goodwin D. Efficacy and safety of switching to 3TC 300 mg QD vs continued 3TC 150 mg BID in subjects with virologic suppression on stable 3TC/d4T/PI therapy (COLA 4005): final 24-week results. 8th Conference on Retroviruses & Opportunistic Infections (CROI), Chicago, Ill., USA, February 2001; Abstract 317.
23. Badaro R, Gathe J, Grimwood A, McLaren C & Klesczewski K. Evaluation of a triple combination regimen containing enteric coated didanosine administered once daily. 1st IAS Conference on HIV Pathogenesis & Treatment, Buenos Aires, Argentina, July 2001; Abstract 57.
24. Robbins G, Shafer R, Smeaton L, De Gruttola V, Pettinelli C, Snyder S, D'Aquila R, Vella S, Merigan T & Hirsch M for the ACTG Team. Antiretroviral strategies in naive HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384). XIV International AIDS Conference, Barcelona, Spain, July 2002; Abstract LbOr20A.
25. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM for the study 006 Team. Efavirenz plus zidovudine and famivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 1999; 341:1865-1873.
26. Saag MS, Tebas P, Sension M, Conant M, Myers R, Chapman SK, Anderson R & Clendeninn N for the Viracept Collaborative Study Group. Randomized, double blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS 2001; 15:1971-1978.
27. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM & Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000; 133:21-30.
28. Bass D & Smith M. HIV patients prefer once-daily regimens. 14th International AIDS Conference, Barcelona, Spain, July 2002; Abstract MoPeB3290.
29. Fauci AS & Bartlett JG, for the Department of Health and Human Services and the Henry J Kaiser Family Foundation. US DHHS Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. February 4, 2002. Available at www.hivatis.org.
30. Barreiro P, Soriano V, Casas E & Gonzalez-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002; 16:245-249.
31. Soriano V. Sequencing antiretroviral drugs. AIDS 2001; 15:547-551.
32. Ross L, Scarsella A, Raffanti S, Henry K, Becker S, Fisher R, Liao Q, Hirani A, Graham N, ST Clair M & Hernandez J for the NZT40012 Study Team. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV 1 isolated from zidovudine-naive patients experiencing viremia on stavudine containing regimens. AIDS Research & Human Retroviruses 2001; 17:1107-1115.
33. Miller V & Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue exposure. Antiviral Therapy 2001; 6(Suppl. 3):25-44.
34. Lange J. A rationale approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm. Antiviral Therapy 2001; 6(Suppl. 3):45-54.
35. Maggiolo F, Callegaro A, Quinzan G, Arici C, Gregis G, Ripamonti D, Goglio A & Suter F. Thymidine associated mutations selection during first HAART. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2002; Abstract P232.